The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical antitumor efficacy of ETN101, a novel oral anticancer agent with Wnt/ß-catenin signaling inhibition, TME modulation, and VEGFR2 targeting for advanced hepatocellular carcinoma treatment.
 
HyeJin Yang
No Relationships to Disclose
 
Yeoun-Hee Kim
No Relationships to Disclose
 
Garam Choi
No Relationships to Disclose
 
Hyun Jin Park
No Relationships to Disclose
 
Yesl Kim
No Relationships to Disclose
 
Min-Jin Choi
No Relationships to Disclose
 
Eunbee Jang
No Relationships to Disclose
 
Sang Heon Jo
No Relationships to Disclose
 
Sarah Kim
No Relationships to Disclose
 
Seonghwan Hwang
No Relationships to Disclose
 
Tae-Jun Kwon
No Relationships to Disclose
 
Dongkyu Kim
No Relationships to Disclose